<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31846303</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-4995</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>04</Day></PubDate></JournalIssue><Title>Biochemistry</Title><ISOAbbreviation>Biochemistry</ISOAbbreviation></Journal><ArticleTitle>Modulating ALS-Related Amyloidogenic TDP-43<sub>307-319</sub> Oligomeric Aggregates with Computationally Derived Therapeutic Molecules.</ArticleTitle><Pagination><StartPage>499</StartPage><EndPage>508</EndPage><MedlinePgn>499-508</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.biochem.9b00905</ELocationID><Abstract><AbstractText>TDP-43 aggregates are a salient feature of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and a variety of other neurodegenerative diseases, including Alzheimer's disease (AD). With an anticipated growth in the most susceptible demographic, projections predict neurodegenerative diseases will potentially affect 15 million people in the United States by 2050. Currently, there are no cures for ALS, FTD, or AD. Previous studies of the amyloidogenic core of TDP-43 have demonstrated that oligomers greater than a trimer are associated with toxicity. Utilizing a joint pharmacophore space (JPS) method, potential drugs have been designed specifically for amyloid-related diseases. These molecules were generated on the basis of key chemical features necessary for blood-brain barrier permeability, low adverse side effects, and target selectivity. Combining ion-mobility mass spectrometry and atomic force microscopy with the JPS computational method allows us to more efficiently evaluate a potential drug's efficacy in disrupting the development of putative toxic species. Our results demonstrate the dissociation of higher-order oligomers in the presence of these novel JPS-generated inhibitors into smaller oligomer species. Additionally, drugs approved by the Food and Drug Administration for the treatment of ALS were also evaluated and demonstrated to maintain higher-order oligomeric assemblies. Possible mechanisms for the observed action of the JPS molecules are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laos</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-0353-2902</Identifier><AffiliationInfo><Affiliation>Department of Chemistry &amp; Biochemistry , University of California, Santa Barbara , Santa Barbara , California 93106 , United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishop</LastName><ForeName>Dezmond</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Chemistry &amp; Biochemistry , University of California, Santa Barbara , Santa Barbara , California 93106 , United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Christian A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Acelot, Inc. , Santa Barbara , California 93111 , United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Nicole M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Chemistry , Westmont College , Santa Barbaraa , California 93108 , United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantrell</LastName><ForeName>Kristi Lazar</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Chemistry , Westmont College , Santa Barbaraa , California 93108 , United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buratto</LastName><ForeName>Steven K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Chemistry &amp; Biochemistry , University of California, Santa Barbara , Santa Barbara , California 93106 , United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Ambuj K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Computer Science , University of California, Santa Barbara , Santa Barbara , California 93106-5110 , United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowers</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><Identifier Source="ORCID">0000-0002-0260-7178</Identifier><AffiliationInfo><Affiliation>Department of Chemistry &amp; Biochemistry , University of California, Santa Barbara , Santa Barbara , California 93106 , United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochemistry</MedlineTA><NlmUniqueID>0370623</NlmUniqueID><ISSNLinking>0006-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075663" MajorTopicYN="N">Ion Mobility Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018625" MajorTopicYN="N">Microscopy, Atomic Force</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31846303</ArticleId><ArticleId IdType="doi">10.1021/acs.biochem.9b00905</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>